Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $197,795.20 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 8,752 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $22.60, for a total value of $197,795.20. Following the completion of the sale, the insider owned 206,995 shares in the company, valued at $4,678,087. The trade was a 4.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

NASDAQ:KMTS traded up $1.16 during trading hours on Monday, reaching $23.99. The company had a trading volume of 373,728 shares, compared to its average volume of 404,856. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. Kestra Medical Technologies, Ltd. has a 1-year low of $14.10 and a 1-year high of $30.00. The business’s 50 day moving average price is $22.62 and its 200-day moving average price is $22.48. The firm has a market cap of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The firm had revenue of $28.64 million for the quarter. Research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on KMTS. Oppenheimer assumed coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating on the stock. BTIG Research lifted their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Finally, Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $27.83.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of KMTS. Seven Grand Managers LLC acquired a new position in shares of Kestra Medical Technologies during the 4th quarter valued at about $2,652,000. Eventide Asset Management LLC increased its position in Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after purchasing an additional 65,288 shares during the last quarter. Summit Partners Public Asset Management LLC purchased a new position in Kestra Medical Technologies during the fourth quarter worth about $9,282,000. Jennison Associates LLC grew its stake in shares of Kestra Medical Technologies by 15.0% in the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock valued at $5,817,000 after buying an additional 28,573 shares during the period. Finally, UBS Group AG increased its holdings in shares of Kestra Medical Technologies by 34.9% during the 4th quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after buying an additional 69,908 shares during the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.